What is the efficacy of isotretinoin (13 cis-retinoic acid) (Accutane) in the treatment of myelodysplastic syndrome (MDS)?

Updated: Jul 24, 2018
  • Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print

Isotretinoin or 13 cis-retinoic acid (Accutane) is the most active retinoid. In a randomized placebo-controlled trial in 70 MDS patients treated with low-dose isotretinoin (20 mg/m2/d), 1-year survival among patients with refractory anemia was 77%, compared with 36% in the placebo group. [26] This is statistically significant, although this form of therapy is not generally accepted. The author limits this treatment to patients who are not transfusion dependent.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!